Counterpart Health Expands Proven Flywheel for HEDIS Excellence to Third-Party Partners
MWN-AI** Summary
Counterpart Health, a subsidiary of Clover Health Investments, has announced the expansion of its AI-driven health technology platform to third-party partners, building on its proven success in achieving top-tier HEDIS (Healthcare Effectiveness Data and Information Set) results. For the second consecutive year, Clover Health has been recognized as the #1 performing PPO plan in the United States for HEDIS clinical quality measures among plans with over 2,000 members. This accomplishment underscores Counterpart’s innovative flywheel model, which optimizes member outcomes without relying on capitation across a diverse network of non-employed physicians.
The HEDIS excellence flywheel comprises several key components: at the point of care, the Counterpart Assistant (CA) identifies clinical gaps, allowing providers to address necessary tests and referrals. The CA also initiates real-time data collection from over 100 sources to create a comprehensive patient view. Utilizing advanced technologies like natural language processing and large language models, Counterpart streamlines the HEDIS abstraction process. Additionally, AI tools help close documentation gaps, enabling primary care physicians (PCPs) to prioritize preventive care over administrative duties.
This approach not only enhances operational efficiency but also improves quality and performance across various health metrics, such as colorectal cancer screenings and diabetic eye exams. CEO Conrad Wai emphasized that by sharing the flywheel model with third-party partners, Counterpart aims to propagate its successful processes, advancing value-based care and optimizing patient outcomes on a broader scale. As Counterpart Health continues its technological evolution, it remains committed to driving better healthcare data and smart AI applications, reinforcing its position as a leader in transforming care delivery and reducing costs nationwide.
MWN-AI** Analysis
Counterpart Health's announcement of expanding its AI-driven HEDIS excellence platform to third-party partners marks a pivotal moment in the healthcare landscape, especially for investors watching Clover Health Investments Corp. (Nasdaq: CLOV). The sustained performance of Clover’s Medicare Advantage plans highlights the efficacy of Counterpart's innovative model, emphasizing data-driven decision-making and quality outcomes.
From a market perspective, this strategic expansion could significantly enhance Clover's competitive advantage in the value-based care sector. By leveraging advanced technologies such as natural language processing and real-time data aggregation from over 100 sources, Counterpart positions itself as a leader in improving healthcare quality metrics while reducing administrative burdens on providers. This dual focus on efficiency and outcomes is particularly attractive in a healthcare environment increasingly focused on accountable care.
Investors should consider the implications of Counterpart's technology on broader industry trends. As more healthcare organizations grapple with the need to improve HEDIS scores—critical for reimbursement rates and overall performance—Counterpart’s platform could become essential. Therefore, Clover's ability to monetize this technology through partnerships could drive revenue growth and improve margins.
Additionally, the company’s proven results in chronic disease management and preventive care suggest a robust market demand for its services. Investors might view Counterpart’s expansion as a sign of sustained growth potential, aligning with increasing healthcare expenditures and a shift towards value-based care delivery models in the United States.
In summary, as Counterpart Health continues to elevate its platform’s reach, investors would be wise to watch for signs of increased adoption rates among third-party partners and any metrics that showcase improved patient outcomes. The ongoing developments could indicate a solid long-term growth trajectory for Clover Health Investments Corp.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN FRANCISCO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Counterpart Health,?Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq:?CLOV) (“Clover,” “Clover?Health” or the “Company”) and a leading AI-powered value-based care enablement company, today announced that its technology platform has once again powered top-tier HEDIS results for Clover Health Medicare Advantage plans through its AI-driven flywheel. The company is now making this unparalleled HEDIS platform available to third-party partners for the first time.
As with last year, Counterpart has enabled Clover Health to be the #1 performing PPO plan in the country for HEDIS clinical quality measures for plans over 2,000 members. Clover is again the only PPO amongst the Top 10 plans, demonstrating our AI platform’s unique ability to drive both member outcomes and plan performance across a wide network of non-employed physicians, without capitation.
Counterpart Health’s flywheel for HEDIS excellence includes:
- CA-powered visits with clinical care gap closure: at the point of care, Counterpart Assistant (CA) surfaces actionable HEDIS clinical gaps for providers to close, whether by validating existing clinical evidence or ordering needed tests or referrals.
- Data ingestion : each CA visit triggers real-time clinical data collection from across the healthcare landscape, aggregating from more than 100 data sources to build a unified patient view.
- AI-powered HEDIS abstraction: Counterpart applies natural language processing (NLP) and large language model (LLM) technologies to identify suspect hits and exclusions for care coordination staff to review.
- HEDIS documentation gap closure: AI-augmented abstraction tooling closes documentation gaps across measures, allowing PCPs to focus on preventive care and clinical action rather than administrative tasks.
This flywheel consistently powers superior results for Clover’s Medicare Advantage population. From a patient outcomes perspective, those who see a CA-powered provider are more likely to meet quality benchmarks on a range of measures, including measures focused on colorectal cancer screening, breast cancer screening, and diabetic eye exams, as demonstrated in a previously published whitepaper .
“This recognition for the second year running reinforces what we know: our technology doesn’t just reduce administrative burden, it directly improves quality and outcomes,” said Conrad Wai, CEO of Counterpart Health. “By opening our HEDIS excellence flywheel to third-party partners, we’re enabling more organizations to benefit from the same proven processes that powered Clover’s industry-leading results.”
As Counterpart Health continues to expand its platform, the company is committed to scaling this model across more partners, driving better data, smarter AI, and higher-quality outcomes for value-based care at scale.
About Counterpart Health
Counterpart Health , a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform transforming care delivery. Born out of Clover Health as Clover Assistant, Counterpart Health’s flagship software platform, Counterpart Assistant, provides clinically intuitive insights that help clinicians better manage chronic conditions and deliver high-quality care. Counterpart Health extends this powerful data-driven technology platform beyond Clover Health’s Medicare Advantage plan, bringing its benefits to a wider audience to improve patient outcomes and reduce healthcare costs nationwide. Several published studies demonstrate the technology’s impact on Diabetes , Chronic Kidney Disease , Congestive Heart Failure , and Chronic Obstructive Pulmonary Disease management, and Clinical Quality .
Investor Relations:
Ryan Schmidt
Press Inquiries:
FAQ**
How does the partnership model for Counterpart Health's HEDIS platform work for third-party organizations, and what benefits can they expect from collaborating with Clover Health Investments Corp. CLOV?
What specific metrics are used to measure the success of Counterpart Health in achieving superior HEDIS results for Clover Health Investments Corp. CLOV's Medicare Advantage plans?
Can you elaborate on how AI technologies, particularly natural language processing, enhance care delivery and outcome measures for Clover Health Investments Corp. CLOV’s patient population?
What future developments can we anticipate from Counterpart Health that may further improve patient outcomes and operational efficiency within Clover Health Investments Corp. CLOV's value-based care model?
**MWN-AI FAQ is based on asking OpenAI questions about Clover Health Investments Corp. (NASDAQ: CLOV).
NASDAQ: CLOV
CLOV Trading
1.77% G/L:
$2.01 Last:
3,562,647 Volume:
$2 Open:
